Publication: Mutations in the tail and rod domains of the neurofilament heavy-chain gene increase the risk of ALS
dc.contributor.coauthor | Marriott, Heather | |
dc.contributor.coauthor | Spargo, Thomas P. | |
dc.contributor.coauthor | Al Khleifat, Ahmad | |
dc.contributor.coauthor | Andersen, Peter M. | |
dc.contributor.coauthor | Cooper-Knock, Johnathan | |
dc.contributor.coauthor | Corcia, Philippe | |
dc.contributor.coauthor | Couratier, Philippe | |
dc.contributor.coauthor | de Carvalho, Mamede | |
dc.contributor.coauthor | Drory, Vivian | |
dc.contributor.coauthor | Gotkine, Marc | |
dc.contributor.coauthor | Landers, John E. | |
dc.contributor.coauthor | McLaughlin, Russell | |
dc.contributor.coauthor | Pardina, Jesus S. Mora | |
dc.contributor.coauthor | Morrison, Karen E. | |
dc.contributor.coauthor | Pinto, Susana | |
dc.contributor.coauthor | Shaw, Christopher E. | |
dc.contributor.coauthor | Shaw, Pamela J. | |
dc.contributor.coauthor | Silani, Vincenzo | |
dc.contributor.coauthor | Ticozzi, Nicola | |
dc.contributor.coauthor | van Damme, Philip | |
dc.contributor.coauthor | van den Berg, Leonard H. | |
dc.contributor.coauthor | Vourc'h, Patrick | |
dc.contributor.coauthor | Weber, Markus | |
dc.contributor.coauthor | Veldink, Jan H. | |
dc.contributor.coauthor | Dobson, Richard J. | |
dc.contributor.coauthor | Schwab, Patrick | |
dc.contributor.coauthor | Al-Chalabi, Ammar | |
dc.contributor.coauthor | Iacoangeli, Alfredo | |
dc.contributor.kuauthor | Başak, Ayşe Nazlı | |
dc.contributor.researchcenter | Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM) | |
dc.contributor.schoolcollegeinstitute | School of Medicine | |
dc.date.accessioned | 2024-12-29T09:36:22Z | |
dc.date.issued | 2024 | |
dc.description.abstract | Objective: Neurofilament heavy-chain gene (NEFH) variants are associated with multiple neurodegenerative diseases, however, their relationship with ALS has not been robustly explored. Still, NEFH is commonly included in genetic screening panels worldwide. We therefore aimed to determine if NEFH variants modify ALS risk. Methods: Genetic data of 11,130 people with ALS and 7,416 controls from the literature and Project MinE were analysed. We performed meta-analyses of published case-control studies reporting NEFH variants, and variant analysis of NEFH in Project MinE whole-genome sequencing data. Results: Fixed-effects meta-analysis found that rare (MAF <1%) missense variants in the tail domain of NEFH increase ALS risk (OR 4.55, 95% CI 2.13-9.71, p < 0.0001). In Project MinE, ultrarare NEFH variants increased ALS risk (OR 1.37 95% CI 1.14-1.63, p = 0.0007), with rod domain variants (mostly intronic) appearing to drive the association (OR 1.45 95% CI 1.18-1.77, p(Madsen-Browning) = 0.0007, p(SKAT-O) = 0.003). While in the tail domain, ultrarare (MAF <0.1%) pathogenic missense variants were also associated with higher risk of ALS (OR 1.94, 95% CI 0.86-4.37, p(Madsen-Browning) = 0.039), supporting the meta-analysis results. Finally, several tail in-frame deletions were also found to affect disease risk, however, both protective and pathogenic deletions were found in this domain, highlighting an intricated architecture that requires further investigation. Interpretation: We showed that NEFH tail missense and in-frame deletion variants, and intronic rod variants are risk factors for ALS. However, they are not variants of large effect, and their functional impact needs to be clarified in further studies. Therefore, their inclusion in routine genetic screening panels should be reconsidered. | |
dc.description.indexedby | WoS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.issue | 7 | |
dc.description.openaccess | gold, Green Published | |
dc.description.publisherscope | International | |
dc.description.sponsors | We would like to thank Dr Ahmad Al Khleifat, Prof. Ammar Al-Chalabi, Prof. Peter M Andersen, Prof. Nazli A. Ba & scedil;ak, Dr Johnathan Cooper-Knock, Prof. Philippe Corcia, Prof. Philippe Couratier, Prof. Mamede de Carvalho, Prof. Vivian Drory, Prof. Jonathan D. Glass, Dr Marc Gotkine, Prof. Orla Hardiman, Dr Alfredo Iacoangeli, Prof. John E. Landers, Dr Russell McLaughlin, Prof. Jesus S. Mora Pardina, Prof. Karen E. Morrison, Dr Susana Pinto, Prof. Monica Povedano, Prof. Christopher E. Shaw, Prof. Pamela J. Shaw, Prof. Vincenzo Silani, Prof. Nicola Ticozzi, Prof. Philip van Damme, Prof. Leonard H. van den Berg, Dr Patrick Vourc'h, Prof. Markus Weber, and Prof. Jan H. Veldink for their contribution to Project MinE. H.M is supported by GlaxoSmithKline and the KCL funded Centre for Doctoral Training (CDT) in Data-Driven Health. T.P.S is an employee of AstraZeneca. A.A.K is funded by ALS Association Milton Safenowitz Research Fellowship (grant number 22-PDF-609. DOI: 10.52546/pc.gr.150909), The Motor Neurone Disease Association (MNDA) Fellowship (Al Khleifat/Oct21/975-799), The Darby Rimmer Foundation, and The NIHR Maudsley Biomedical Research Centre. P.S is an employee and shareholder of GlaxoSmithKline plc. A.I is funded by the Motor Neurone Disease Association, MND Scotland, Darby Rimmer MND Foundation, Rosetrees Trust, Alzheimer's Research UK, Spastic Paraplegia Foundation and The NIHR Maudsley Biomedical Research Centre. A.A-C is an NIHR Senior Investigator (NIHR202421) and has received support from an EU Joint Programme-Neurodegenerative Disease Research (JPND) project. The work is supported through the following funding organisations under the aegis of JPND- (United Kingdom, Medical Research Council (MR/L501529/1; MR/R024804/1) and Economic and Social Research Council (ES/L008238/1)) and through the Motor Neurone Disease Association, My Name'5 Doddie Foundation, Wellcome Trust, MRC Medical Research Council, and Alan Davidson Foundation. This study represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The authors acknowledge use of the research computing facility at King's College London, Rosalind (), and King's College HPC Create (King's College London. (2022). King's Computational Research, Engineering and Technology Environment (CREATE). Retrieved 2 March 2022, from ). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. | |
dc.description.volume | 11 | |
dc.identifier.doi | 10.1002/acn3.52083 | |
dc.identifier.issn | 2328-9503 | |
dc.identifier.quartile | Q1 | |
dc.identifier.scopus | 2-s2.0-85195660655 | |
dc.identifier.uri | https://doi.org/10.1002/acn3.52083 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/22026 | |
dc.identifier.wos | 1228829600001 | |
dc.keywords | Structural variants | |
dc.language | en | |
dc.publisher | WILEY | |
dc.source | Annals of Clinical and Translational Neurology | |
dc.subject | Clinical neurology | |
dc.subject | Neurosciences | |
dc.title | Mutations in the tail and rod domains of the neurofilament heavy-chain gene increase the risk of ALS | |
dc.type | Journal article | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Başak, Ayşe Nazlı |